CA2346326A1 - A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers - Google Patents
A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers Download PDFInfo
- Publication number
- CA2346326A1 CA2346326A1 CA002346326A CA2346326A CA2346326A1 CA 2346326 A1 CA2346326 A1 CA 2346326A1 CA 002346326 A CA002346326 A CA 002346326A CA 2346326 A CA2346326 A CA 2346326A CA 2346326 A1 CA2346326 A1 CA 2346326A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- esbpii
- levels
- patient
- gynecologic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Radiology & Medical Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating prostate cancer and gynecologic cancers including breast, endometrial, ovarian and uterine cancer.
Description
A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING AND TREATING GYNECOLOGICAL
AND
PROSTATIC CANCERS
FIELD OF THE INVENTION
This invention relates, in part, to newly developed assays for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating cancers, particularly gynecologic cancers including uterine, endometrial, breast and ovarian cancer, and prostate cancer.
BACKGROUND OF THE INVENTION
In women, gynecologic cancers account for more than one-fourth of the malignancies.
For example, endometrial cancer occurs at a rate of approximately 44,500 new cases per year with approximately 10,000 deaths per year. If diagnosed and treated early, when the cancer is still confined to the endometrium, cure can be achieved in approximately 95~s of the cases by hysterectomy.
Pap smears can show endometrial cancers but are effective in only 50°s of the cases. For the remainder, abnormal vaginal bleeding is typically the first clinical sign of endometrial cancer.
Sarcoma of the uterus, a very rare kind of cancer in women, is a disease in which cancer (malignant) cells start growing in the muscles or other supporting tissues of the uterus. Sarcoma of the uterus is different from cancer of the endometrium, a disease in which cancer cells start growing in the lining of the uterus. Women who have received therapy with high-dose x-rays (external beam radiation therapy) to their pelvis are at a higher risk to develop sarcoma of the uterus. These x-rays are sometimes given to women to stop bleeding from the uterus. Like most cancers, sarcoma of the uterus is best treated when it is found (diagnosed) early.
Sarcoma of the uterus usually begins after menopause. When a patient has signs of such cancer, an internal pelvic examination is usually performed to detect any lumps or changes in shape of the pelvic organs. A Pap test may also be performed, however because sarcoma of the uterus begins inside the organ, this cancer is not usually detected by the Pap test. A dilation and curettage (D&C) may also be performed and a biopsy sample taken and examined microscopically.
It is estimated that one of every nine women in America will develop breast cancer sometime during her life based on a lifespan of 85 years. Annually, over 180,000 women in the United States are diagnosed with breast cancer and approximately 46,000 die from this disease. Every woman is at risk for breast cancer. However, a woman's chances of developing breast cancer increase as she grows older; 80 percent of all cancers are found in women over the age of 50.
There are also several risk factors that can increase a woman's chances of developing breast cancer. These include a family history of breast cancer, having no children or the first child after the age of 30, and an early start of menstruation. However, more than 70 percent of women who develop breast cancer have no known risk factors. Less than 10 percent of breast cancer cases are thought to be related to the BRCA1 gene discovered in 1994. Researchers are now investigating the role of other factors such as nutrition, alcohol, exercise, smoking, and oral contraceptives in development of this gynecologic cancer. Mammograms, or special x-rays of the breast, can detect more than 90 percent of all cancers.
Carcinoma of the ovary is another very common gynecologic cancer. In fact, ovarian cancer causes more deaths than any other cancer of the female reproductive system. Approximately one in 70 women develop ovarian cancer during their lifetime. An estimated 14,500 deaths in 1995 resulted from ovarian cancer. Ovarian cancer often does not cause any noticeable symptoms. Possible warning signals include an enlarged abdomen due to an accumulation of fluid or vague digestive disturbances (discomfort, gas or distention) in women over 40. In rare cases abnormal vaginal bleeding also occurs. Pap tests do not detect ovarian cancer., Thus, periodic, complete pelvic examinations are important and recommended annually for women over 40.
In men, cancer of the prostate is the most prevalent malignancy, excluding skin cancer, and is an increasingly prevalent health problem in the United States. In 1996, it was estimated that in the United States, 41,400 deaths would result from this disease, indicating that prostate cancer is second only to lung cancer as the most common cause of death in the same population. Treatment decisions for an individual are linked to the stage of prostate cancer present in that individual. A common classification of the spread of prostate cancer was developed by the American Urological Association (AUA). The AUA classification divides prostate tumors into four stages, A to D. Stage A, microscopic cancer within prostate, is further subdivided into stages A1 and A2. Sub-stage A1 is a well-differentiated cancer confined to one site within the prostate. Treatment is generally observation, radical prostatectomy, or radiation. Sub-stage A2 is a moderately to poorly differentiated cancer at multiple sites within the prostate. Treatment is radical prostatectomy or radiation. Stage B, palpable lump within the prostate, is further subdivided into stages B1 and B2. In sub-stage B1, the cancer forms a small nodule in one lobe of the prostate.
In sub-stage B2, the cancer forms large or multiple nodules, or occurs in both lobes of the prostate. Treatment for both sub-stages B1 and B2 is either radical prostatectomy or radiation. Stage C is a large cancer mass involving most or all of the prostate and is further subdivided into two stages.
AND
PROSTATIC CANCERS
FIELD OF THE INVENTION
This invention relates, in part, to newly developed assays for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating cancers, particularly gynecologic cancers including uterine, endometrial, breast and ovarian cancer, and prostate cancer.
BACKGROUND OF THE INVENTION
In women, gynecologic cancers account for more than one-fourth of the malignancies.
For example, endometrial cancer occurs at a rate of approximately 44,500 new cases per year with approximately 10,000 deaths per year. If diagnosed and treated early, when the cancer is still confined to the endometrium, cure can be achieved in approximately 95~s of the cases by hysterectomy.
Pap smears can show endometrial cancers but are effective in only 50°s of the cases. For the remainder, abnormal vaginal bleeding is typically the first clinical sign of endometrial cancer.
Sarcoma of the uterus, a very rare kind of cancer in women, is a disease in which cancer (malignant) cells start growing in the muscles or other supporting tissues of the uterus. Sarcoma of the uterus is different from cancer of the endometrium, a disease in which cancer cells start growing in the lining of the uterus. Women who have received therapy with high-dose x-rays (external beam radiation therapy) to their pelvis are at a higher risk to develop sarcoma of the uterus. These x-rays are sometimes given to women to stop bleeding from the uterus. Like most cancers, sarcoma of the uterus is best treated when it is found (diagnosed) early.
Sarcoma of the uterus usually begins after menopause. When a patient has signs of such cancer, an internal pelvic examination is usually performed to detect any lumps or changes in shape of the pelvic organs. A Pap test may also be performed, however because sarcoma of the uterus begins inside the organ, this cancer is not usually detected by the Pap test. A dilation and curettage (D&C) may also be performed and a biopsy sample taken and examined microscopically.
It is estimated that one of every nine women in America will develop breast cancer sometime during her life based on a lifespan of 85 years. Annually, over 180,000 women in the United States are diagnosed with breast cancer and approximately 46,000 die from this disease. Every woman is at risk for breast cancer. However, a woman's chances of developing breast cancer increase as she grows older; 80 percent of all cancers are found in women over the age of 50.
There are also several risk factors that can increase a woman's chances of developing breast cancer. These include a family history of breast cancer, having no children or the first child after the age of 30, and an early start of menstruation. However, more than 70 percent of women who develop breast cancer have no known risk factors. Less than 10 percent of breast cancer cases are thought to be related to the BRCA1 gene discovered in 1994. Researchers are now investigating the role of other factors such as nutrition, alcohol, exercise, smoking, and oral contraceptives in development of this gynecologic cancer. Mammograms, or special x-rays of the breast, can detect more than 90 percent of all cancers.
Carcinoma of the ovary is another very common gynecologic cancer. In fact, ovarian cancer causes more deaths than any other cancer of the female reproductive system. Approximately one in 70 women develop ovarian cancer during their lifetime. An estimated 14,500 deaths in 1995 resulted from ovarian cancer. Ovarian cancer often does not cause any noticeable symptoms. Possible warning signals include an enlarged abdomen due to an accumulation of fluid or vague digestive disturbances (discomfort, gas or distention) in women over 40. In rare cases abnormal vaginal bleeding also occurs. Pap tests do not detect ovarian cancer., Thus, periodic, complete pelvic examinations are important and recommended annually for women over 40.
In men, cancer of the prostate is the most prevalent malignancy, excluding skin cancer, and is an increasingly prevalent health problem in the United States. In 1996, it was estimated that in the United States, 41,400 deaths would result from this disease, indicating that prostate cancer is second only to lung cancer as the most common cause of death in the same population. Treatment decisions for an individual are linked to the stage of prostate cancer present in that individual. A common classification of the spread of prostate cancer was developed by the American Urological Association (AUA). The AUA classification divides prostate tumors into four stages, A to D. Stage A, microscopic cancer within prostate, is further subdivided into stages A1 and A2. Sub-stage A1 is a well-differentiated cancer confined to one site within the prostate. Treatment is generally observation, radical prostatectomy, or radiation. Sub-stage A2 is a moderately to poorly differentiated cancer at multiple sites within the prostate. Treatment is radical prostatectomy or radiation. Stage B, palpable lump within the prostate, is further subdivided into stages B1 and B2. In sub-stage B1, the cancer forms a small nodule in one lobe of the prostate.
In sub-stage B2, the cancer forms large or multiple nodules, or occurs in both lobes of the prostate. Treatment for both sub-stages B1 and B2 is either radical prostatectomy or radiation. Stage C is a large cancer mass involving most or all of the prostate and is further subdivided into two stages.
In sub-stage C1, the cancer forms a continuous mass that may have extended beyond the prostate. In sub-stage C2, the cancer forms a continuous mass that invades the surrounding tissue. Treatment for both these sub-stages is radiation with or without drugs. The fourth stage is metastatic cancer and is also subdivided into two stages. In sub-stage Dl, the cancer appears in the lymph nodes of the pelvis. In sub-stage D2, the cancer involves tissues beyond lymph nodes. Treatment for both these sub-stages is systemic drugs to address the cancer as well as pain.
In all of these cancers, chances of survival are much better if the cancer is diagnosed at an early stage. Further, treatment decisions for the individual are linked to the stage of the cancer present in that individual. However, current cancer staging methods are limited and some such cancers initially staged as not metastatic are actually metastatic.
For example, as many as 500 of the cases of prostate cancer initially staged as A2, B, or C are actually stage D, metastatic. Discovery of metastasis is significant because patients with metastatic cancers have a poorer prognosis and require significantly different therapy than those with localized cancers.
Accordingly, there is a great need for sensitive and accurate methods for early detection and staging of gynecologic cancers such as endometrial, breast, uterine and ovarian cancer and prostate cancer in humans.
Steroid binding proteins, including uteroglobin and CC10, are a class of proteins which bind steroids along with methylsulfonyl metabolites of polychlorinated biphenyls. The exact function of members of this class of protein is uncertain. However, uteroglobin has been shown to inhibit PLA2 mediated responses.
Gene and gene products homologous to uteroglobin are described in WO 97/34997 entitled Human Endometrial Specific Steroid Binding Factors I, II and III. The genes and their encoded products are referred to as Human Endometrial Specific Steroid-Binding Factors I, II and III (hESF I, II, and III).
Methods for utilizing these genes and gene products in research and diagnostic and clinical arts are disclosed.
In particular, methods for detecting mutations in the hESFI, II or III gene or altered protein expression resulting from a mutant gene are indicated to be useful in diagnosing, susceptibility to asthma and endometrial cancer.
A novel member of the uteroglobin family which is very similar to hESF II, referred to as BU101, is also described in WO 98/07857. BU101 is disclosed to be over-expressed in a percentage of breast tumors. Therefore, BU101 is suggested to be useful for the detecting, diagnosing staging, monitoring, prognosticating, preventing, treating and determining the predisposition of an individual to diseases and conditions of the breast such as breast cancer.
In WO 98/56248 methods for diagnosing breast cancer, endometrial cancer, endometriosis and endometrial fibroids via detection of a gene or gene product referred to therein as ESBPII and identical to BU101 are disclosed.
It has now been found that detection of ESBPII is also useful in diagnosing, monitoring, staging, prognosticating, imaging and treating uterine, ovarian and prostate cancer.
Accordingly, in the present invention, methods are provided for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating prostate cancer and gynecologic cancers including not only breast and endometrial cancer, but also uterine and ovarian cancer via ESBPII.
ESBPII refers, among other things, to native protein expressed by the gene comprising the polynucleotide sequence of SEQ ID
NO:1. The amino acid sequence of a polypeptide encoded by SEQ
ID N0:1 is depicted herein as SEQ ID N0:2. In the alternative, what is meant by the ESBPII as used herein, means the native mRNA encoded by the gene comprising the polynucleotide sequence of SEQ ID N0:1 or levels of the gene comprising the polynucleotide sequence of SEQ ID NO:1.
Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.
SUN~1ARY OF THE INVENTION
Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of prostate cancer or gynecologic cancers by analyzing for changes in levels of ESBPII in cells, tissues or bodily fluids compared with levels of ESBPII in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein a change in levels of ESBPII in the patient versus the normal human control is associated with prostate cancer or a gynecologic cancer.
Further provided is a method of diagnosing metastatic prostate cancer or a metastatic gynecologic cancer in a patient which is not known to have metastasized by identifying a human patient suspected of having prostate cancer or a gynecologic cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for ESBPII; and comparing the ESBPII levels in such cells, tissues, or bodily fluid with levels of ESBPII in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in ESBPII levels in the patient versus the normal human control is associated with prostate cancer or a gynecologic cancer which has metastasized.
Also provided by the invention is a method of staging prostate cancer or a gynecologic cancer in a human by identifying a human patient having prostate cancer or a gynecologic cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for ESBPII; comparing ESBPII
levels in such cells, tissues, or bodily fluid with levels of ESBPII in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in ESBPII
levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of ESBPII is associated with a cancer which is regressing or in remission.
Further provided is a method of monitoring prostate cancer or a gynecologic cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for ESBPII;
comparing the ESBPII levels in such cells, tissue, or bodily fluid with levels of ESBPII in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in ESBPII levels in the patient versus the normal human control is associated with a cancer which has metastasized.
Further provided is a method of monitoring the change in stage of prostate cancer or a gynecologic cancer in a human patient by monitoring levels of ESBPII in the patient. The method comprises identifying a human patient having prostate cancer or a gynecologic cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for ESBPII; comparing the ESBPII levels in such cells, tissue, or bodily fluid with levels of ESBPII in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in ESBPII levels in the patient versus the normal human control is associated with a cancer _ g _ which is progressing and a decrease in the levels of ESBPII
is associated with a cancer which is regressing or in remission.
Further provided are antibodies which specifically bind ESBPII or fragments of such antibodies which can be used to detect or image localization of ESBPII in a patient for the purpose of detecting or diagnosing prostate cancer or a gynecologic cancer. Such antibodies can be polyclonal, monoclonal, or omniclonal or prepared by molecular biology techniques. The term "antibody", as used herein and throughout the instant specification is also meant to include aptamers and single-stranded oligonucleotides such as those derived from an in vitro evolution protocol referred to as SELEX and well known to those skilled in the art. Antibodies can be labeled with a variety of detectable labels including, but not limited to, radioisotopes and paramagnetic metals.
These antibodies or fragments thereof can also be used as therapeutic agents in the treatment of diseases characterized by expression of a ESBPII. In therapeutic applications, the antibody can be used without or with derivatization to a cytotoxic agent such as a radioisotope, enzyme, toxin, drug or a prodrug.
Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.
_ g _ DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging and prognosticating cancers by comparing levels of ESBPII with those of ESBPII in a normal human control. What is meant by levels of ESBPII as used herein, means levels of the native protein expressed by the gene comprising the polynucleotide sequence of SEQ ID NO:1.
The polypeptide encoded by this polynucleotide sequence is depicted in SEQ ID N0:2. In the alternative, what is meant by levels of ESBPII as used herein, mean levels of the native mRNA encoded by the gene comprising the polynucleotide sequence of SEQ ID NO:l or levels of the gene comprising the polynucleotide sequence of SEQ ID NO:1. Such levels are I5 preferably measured in at least one of cells, tissues and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing overexpression of ESBPII
protein compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of cancers, including prostate cancer and gynecologic cancers such as uterine, endometrial, breast and ovarian cancer.
All the methods of the present invention may optionally include measuring levels of other cancer markers as well as ESBPII. Other cancer markers, in addition to ESBPII, useful in the present invention will depend on the cancer being tested and are known to those of skill in the art.
Diagnostic Assays The present invention provides methods for diagnosing the presence of prostate cancer or gynecologic cancers including breast, uterine, ovarian and endometrial cancer by analyzing for changes in levels of ESBPII in cells, tissues or bodily fluids of a human patient compared with levels of ESBPII in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein an increase in levels of ESBPII in the patient versus the normal human control is associated with the presence of prostate cancer or a gynecologic cancer.
Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues or bodily fluid levels of the cancer marker, such as ESBPII, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control.
The present invention also provides a method of diagnosing the onset of metastasis in human patients with a gynecologic cancer or prostate cancer. In this method, a human cancer patient suspected of having a gynecologic cancer or prostate cancer which may have metastasized (but which was not previously known to have metastasized) is identified.
This is accomplished by a variety of means known to those of skill in the art.
In the present invention, determining the presence of ESBPII levels in cells, tissues or bodily fluid, is particularly useful for discriminating between prostate cancer or a gynecologic cancer which has not metastasized and prostate cancer or a gynecologic cancer which has metastasized. Existing techniques have difficulty discriminating between prostate cancer or gynecologic cancers which have metastasized and prostate cancer or gynecologic cancers which have not metastasized. However, proper treatment selection is often dependent upon such knowledge.
In the present invention, the cancer marker level measured in such cells, tissues or bodily fluid is ESBPII.
Measured ESBPII levels in a human patient are compared with levels of ESBPII in preferably the same cells, tissue or bodily fluid type of a normal human control. That is, if the cancer marker being observed is ESBPII in serum, this level is preferably compared with the level of ESBPII in serum of a normal human control. An increase in the ESBPII in the patient versus the normal human control is associated with prostate cancer or a gynecologic cancer which has metastasized.
Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues or bodily fluid levels of a cancer marker, such as ESBPII, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily fluid of a normal patient.
Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing or monitoring for metastasis, normal human control may preferably include samples from a human patient that is determined by reliable methods to have prostate cancer or a gynecologic cancer which has not metastasized.
Staging The invention also provides a method of staging prostate cancer or gynecologic cancers in a human patient. The method comprises identifying a human patient having prostate cancer or a gynecologic cancer and analyzing cells, tissues or bodily fluid from such human patient for levels of ESBPII.
The levels of ESBPII in the patient are then compared to levels of ESBPII in preferably the same cells, tissues or bodily fluid type of a normal human control, wherein an increase in ESBPII levels in the human patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of ESBPII is associated with a cancer which is regressing or in remission.
Monitoring Further provided is a method of monitoring prostate cancer or gynecologic cancers in a human patient having such cancer for the onset of metastasis. The method comprises identifying a human patient having prostate cancer or a gynecologic cancer that is not known to have metastasized;
periodically analyzing cells, tissues or bodily fluid from such human patient for ESBPII; comparing the ESBPII levels in such cells, tissues or bodily fluid with levels of ESBPII in preferably the same cells, tissues or bodily fluid type of a normal human control, wherein an increase in ESBPII levels in the human patient versus the normal human control is associated with a cancer which has metastasized.
Further provided by this invention is a method of monitoring the change in stage of prostate cancer or a gynecologic cancer in a human having such cancer. The method comprises identifying a human patient having prostate cancer or a gynecologic cancer; periodically analyzing cells, tissues or bodily fluid from such human patient for ESBPII; and comparing the ESBPII levels in such cells, tissues or bodily fluid with levels of ESBPII in preferably the same cells, tissues or bodily fluid type of a normal human control sample, wherein an increase in ESBPII levels in the human patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of ESBPII is associated with a cancer which is regressing in stage or in remission.
Monitoring such patient for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.
Assay Techniques Assay techniques that can be used to determine levels of gene expression (including protein levels), such as ESBPII
of the present invention, in a sample derived from a patient are well known to those of skill in the art. Such assay methods include, without limitation, radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, in situ hybridization assays, competitive-binding assays, Western Blot analyses, ELISA
assays and proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel based approaches such as mass spectrometry or protein interaction profiling. Among these, ELISAs are frequently preferred to diagnose a gene's expressed protein in biological fluids.
An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to ESBPII, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds specifically to ESBPII. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent. Examples include, but are not limited to, horseradish peroxidase enzyme and alkaline phosphatase.
To carry out the ELISA, antibody specific to ESBPII is incubated on a solid support, e.g. a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time ESBPII
binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to ESBPII and linked to a detectable reagent such as horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to ESBPII. Unattached reporter antibody is then washed out. Reagents for peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to ESBPII
antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of ESBPII protein present in the sample.
Quantitative results typically are obtained by reference to a standard curve.
A competition assay can also be employed wherein antibodies specific to ESBPII are attached to a solid support and labeled ESBPII and a sample derived from the host are passed over the solid support. The amount of label detected which is attached to the solid support can be correlated to a quantity of ESBPII in the sample.
Nucleic acid methods can also be used to detect ESBPII
mRNA as a marker for prostate cancer and gynecologic cancers.
Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA
species is first reverse transcribed to complementary DNA
(cDNA) with use of the enzyme reverse transcriptase; the cDNA
is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.
Hybridization to clones or oligonucleotides arrayed on a solid support (i.e. gridding) can be used to both detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the ESBPII gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or plastic. At least a portion of the DNA encoding the ESBPII
gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest.
Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be done by comparison of the intensity of the signal from the analyte compared with that determined from known standards.
The standards can be obtained by in vitro transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.
Of the proteomic approaches, 2D electrophoresis is a technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels.
First, proteins are separated by size using an electric current. The current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins.
The second dimension applies a current perpendicular to the first and separates proteins not on the basis of size but on the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot.
Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.
The above tests can be carried out on samples derived from a variety of cells, bodily fluids and/or tissue extracts (homogenates or solubilized tissue) obtained from the patient including tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof. Blood can include whole blood, plasma, serum or any derivative of blood.
In Vivo Antibody Use Antibodies against ESBPII can also be used in vivo in patients suspected of suffering from prostate cancer or gynecologic cancers such as ovarian, breast, endometrial and uterine cancer. Specifically, antibodies against a ESBPII can be injected into a patient suspected of having prostate cancer or a gynecologic cancer for diagnostic and/or therapeutic, purposes. The use of antibodies for in vivo diagnosis is well known in the art. For example, antibody-chelators labeled with Indium-111 have been described for use in the radioimmunoscintographic imaging of carcinoembryonic antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990 17:247-259). In particular, these antibody-chelators have been used in detecting tumors in patients suspected of having recurrent colorectal cancer (Griffin et al. J. Clin. Onc. 1991 9:631-640). Antibodies with paramagnetic ions as labels for use in magnetic resonance imaging have also been described (Lauffer, R.B. Magnetic Resonance in Medicine 1991 22:339-342). Antibodies directed against ESBPII can be used in a similar manner. Labeled antibodies against ESBPII can be injected into patients suspected of having a gynecologic cancer or prostate cancer for the purpose of diagnosing or staging of the disease status of the patient. The label used will be selected in accordance with the imaging modality to be used. For example, radioactive labels such as Indium-111, Technetium-99m or Iodine-131 can be used for planar scans or single photon emission computed tomography (SPELT). Positron emitting labels such as Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadlinium (III) or Manganese (II) can be used in magnetic resonance imaging (MRI). Localization of the label permits determination of the spread of the cancer. The amount of label within an organ or tissue also allows determination of the presence or absence of cancer in that organ or tissue.
For patients diagnosed with prostate cancer or a gynecologic cancer, injection of an antibody against ESBPII
can also have a therapeutic benefit. The antibody may exert its therapeutic effect alone. Alternatively, the antibody is conjugated to a cytotoxic agent such as a drug, toxin or radionuclide to enhance its therapeutic effect. Drug monoclonal antibodies have been described in the art for example by Garnett and Baldwin, Cancer Research 1986 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various cancers has also been described by Pastan et al. Cell 1986 97:641-648. Yttrium-90 labeled monoclonal antibodies have been described for maximization of dose delivered to the tumor while limiting toxicity to normal tissues (Goodwin and Meares Cancer Supplement 1997 80:2675-2680). Other cytotoxic radionuclides including, but not limited to Copper-67, Iodine-131 and Rhenium-186 can also be used for labeling of antibodies against ESBPII.
Antibodies which can be used in these in vivo methods include both polyclonal, monoclonal or omniclonal antibodies and antibodies prepared via molecular biology techniques.
Antibody fragments and aptamers and single-stranded oligonucleotides such as those derived from an in vitro evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.
The present invention is further described by the following examples. These examples are provided solely to illustrate the invention by reference to specific embodiments.
These exemplifications, while illustrating certain aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.
EXAMPLES
The examples are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. Routine molecular biology techniques of the following example can be carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
(1989) .
Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye.
During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).
Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ATP synthase 6 (ATPsy6), or 18S ribosomal RNA (rRNA} is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA
levels for one sample are used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).
The tissue distribution and the level of the target gene for every example was evaluated in normal and cancer tissue.
Total RNA was extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was done using primers and Taqman probe specific to the target gene. The results were analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.
The absolute numbers depicted in Table 1 are relative levels of expression of ESBPII in 12 normal different tissues.
All the values are compared to normal lung (calibrator).
These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.
Table 1: Relative Levels of ESBPII Expression in Pooled Samples TISSUE NORMAL
Brain 28 Heart 50 Kidney 374 Liver 3 Lung 1 Breast 10885 Prostate 590 Small Intestine 60 Spleen 1 Testis 308 Thymus 8 Uterus 16047 The relative levels of expression in Table 1 show that the highest level of expression of ESBPII mRNA is in uterus (16047) and the second highest levels of expression is in mammary gland (10885). Prostate (590), kidney (374), and testis (308) also express mRNA for ESBPII. These results established that ESBPII mRNA expression is highly specific for uterus and breast in female tissues, and prostate for male tissues.
The absolute numbers in Table 1 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 2.
The absolute numbers depicted in Table 2 are relative levels of expression of ESBPII in 76 pairs of matching samples, ovarian cancer samples from 15 different individuals, and normal ovarian samples from 15 different individual s. All the values are compared to normal lung (calibrator). A
matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.
Table 2: Relative Levels of ESBPII Expression in Pooled Samples Sample ID Tissue Cancer Normal Normal Adjacent Tissue End10479 Endometrium 1 1189 143 End8911 Endometrium 2 989 15772 END012XA Endometrium 3 2226 6724 END028XA Endometrium 9 14767 6701 END03AX Endometrium 5 1284 2864 END05XA Endometrium 6 20857 38388 END065RA Endometrium 7 151825 1515 END08XA Endometrium 8 115 4097 End8963 Endometrium 9 149010 13308 End4XA Endometrium 10 274 12945 End68X Endometrium 11 751834 759691 BLD32XK Bladder 1 1 0 BLD46XK Bladder 2 26 21 CLNAS45 Colon 1 1 1 CLNRCO1 Colon 2 0 2 C1nB34 Colon 3 0 3 CvxKS52 Cervix 1 0 17 CvxNKSl8 Cervix 2 0 20 CvxNKs80 Cervix 3 0 778347 Kid107XD Kidney 1 1734 1239 Kid106XD Kidney 2 125 699 Kid109XD Kidney 3 274 637 KidlOXD Kidney 4 5814 1892 KidllXD Kidney 5 423 537 Kid124D Kidney 6 100 332 Kidl2XD Kidney 7 467 287 Kid150D Kidney 8 1862 134 Kid373K Kidney 9 388 330 KidSXD Kidney 10 1239 1061 Kid98XD Kidney 11 100 391 LIV15XA Liver 1 3 2 Liv94XA Liver 2 39 0 Lng60XL Lung 1 0 2 LngSQ81 Lung 2 0 12 LNGC20X Lung 3 5 26 Mam47XP Breast 1 1448 177 Mam82XI Breast 2 24 246 MamA06X Breast 3 10865 6047 MamBOIIX Breast 4 12915 1194 Mam59X Breast 5 648 119 MamS079 Breast 6 24 33 MamS123 Breast 7 81282 1598 MamS516 Breast 8 5827 987 MamS570 Breast 9 6125 15555 PAN71XL Pancreas 1 12 18 Pan82XP Pancreas 2 56 383 Pan77X Pancreas 3 0 0 Prol8XB Prostate 1 959 2798 Pro20XB Prostate 2 9642 2084 Pro69XB Prostate 3 2041 171 Pro90XB Prostate 4 251 3916 Pro65XB Prostate 5 1296 832 Pro101XB Prostate 6 2896 5753 Prol2B Prostate 7 2750 111 Prol3XB Prostate 8 33 551 Pro23B Prostate 9 310 309 Pro34B Prostate 10 1261 1180 Pro78XB Prostate 11 666 697 Pro84XB Prostate 12 3214 972 Pro9lX Prostate 13 3835 989 ProC215 Prostate 19 5312 nd ProC234 Prostate 15 549 nd ProC280 Prostate 16 873 nd SmInt2lXA Small Intestine 9 12 SmInH89 Small Intestine 2 25 StoAC44 Stomach 1 4 4 StoAC99 Stomach 2 3 2 Tst39X Testis 1 29 146 UTR135X0 Uterus 1 2055 3616 UTR141X0 Uterus 2 69516 8024 UTR85XU Uterus 3 2947 7083 UTR23XU Uterus 4 52501 6361 Ovr103X Ovary 1 760 4 Ovr130X Ovary 2 1 77 OvrG010 Ovary 3 1670 108 OvrG021 Ovary 4 6 21 Ovr1005 Ovary Cancer 1 4716 Ovr1040 Ovary Cancer 2 2235 Ovr638A Ovary Cancer 3 6 Ovr63A Ovary Cancer 4 9 Ovr1028 Ovary Cancer 5 8 Ovr1050 Ovary Cancer 6 629 Ovr1118 Ovary Cancer 7 2 Ovr1157 Ovary Cancer 8 2694 Ovr130X Ovary Cancer 9 1587 Ovr1461 Ovary Cancer 10 0 Ovr180B Ovary Cancer 11 3104 Ovr3710 Ovary Cancer 12 803 Ovr63A Ovary Cancer 13 7 OvrAlC Ovary Cancer 14 4251 OvrC360 Ovary Cancer 15 3 OvrlBGA Ovary Normal 1 4 Ovr2061 Ovary Normal 2 28 Ovr20GA Ovary Normal 3 Ovr230A Ovary Normal 4 28 Ovr233A Ovary Normal 5 0 Ovr247A Ovary Normal 6 113 Ovr25GA Ovary Normal 7 88 Ovr32RA Ovary Normal 8 47 Ovr6380 Ovary Normal 9 23 OvrC0009 Ovary Normal 10 16 OvrC179 Ovary Normal 11 8 Ovr35GA Ovary Normal 12 18 Ovr40G Ovary Normal 13 1 Ovr50GB Ovary Normal 14 2 Ovr9RA Ovary Normal 15 2 0= Negative nd=Not Determined In the analysis of matching samples, the higher levels of expression were in uterus, endometrium, breast, ovary, and prostate. There is also a lower expression of ESBPII in the kidney matching samples analyzed. The median expression in the kidney cancer samples (423), is one third the median expression in the prostate cancer samples (1279). This pattern shows a high degree of specificity for female gynecologic tissues and prostate tissue. These results confirmed the tissue specificity results obtained with the panel of normal pooled samples (Table 1) for uterus, breast and prostate.
Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e. g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 2 shows overexpression of ESBPII in 4 primary endometrial cancer tissues compared with their respective normal adjacent (endometrium samples #l, 4, 7, and 9). There was overexpression in the cancer tissue for 36.36 of the endometrial matching samples tested (total of 11 endometrium matching samples).
ESBPII is differentially expressed in the four matching samples for uterine cancer. Samples #1 and 3 show downregulation for the mRNA of ESBPII in cancer, whereas samples #2 and #4 show overexpression in the cancer samples.
Of nine breast cancer matching samples analyzed, three showed underexpression of ESBPII (#2, 6, and 9) in cancer, whereas six had higher levels of ESBPII in cancer compared to the normal adjacent tissue (#1, 3, 4, 5, 7, and 8).
ESBPII is differentially expressed in the four matching samples for ovarian cancer. Samples #1 and 3 showed upregulation for the mRNA of ESBPII in cancer, whereas samples #2 and #4 showed overexpression in the normal adjacent tissue.
Beside the four matching samples, thirty additional ovarian samples were analyzed. Fifteen cancer samples and 15 normal ovary tissue samples from different individuals. The median expression in the ovary cancer samples (629) is four times higher than the median expression in the normal ovary samples (16) .
Altogether, the high level of tissue specificity for gynecological tissues, plus the mRNA differential expression in several of the primary uterus, endometrial, breast, and ovarian matching samples tested are indicative of ESBPII being a diagnostic marker for gynecologic cancers including uterine, endometrial, breast, and ovarian cancer. ESBPIT is also differentially expressed in the 13 matching samples for prostate cancer. Samples #l, 4, 6, 8, and 11 showed downregulation of the mRNA of ESBPII in cancer, whereas samples #2, 3, 5, 7, 9, 10, 12, and 13 showed overexpression in the cancer tissue. The median expression in the prostate cancer samples (1279) is higher than the median expression in the normal prostate samples (972).
Altogether, the high level of tissue specificity for prostate tissue, plus the mRNA differential expression in several of the primary prostate matching samples tested are indicative of ESBPII being a diagnostic marker for prostate cancer.
SEQUENCE LISTING
<110> Macina, Roberto A.
DIADEXUS LLC
<120> A Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Gynecologic Cancers and Prostate Cancer <130> DEX-0046 <140>
<141>
<150> 60/103,093 <151> 1998-10-05 <160> 2 <170> PatentIn Ver. 2.0 <210> 1 <211> 436 <212> DNA
<213> Homo Sapiens <400> 1 ttgtttgtga aagctgagct cacagcaaaa caagccacca tgaagctgtc ggtgtgtctc 60 ctgctggtca cgctggccct ctgctgctac caggccaatg ccgagttctg cccagctctt 120 gtttctgagc tgttagactt cttcttcatt agtgaacctc tgttcaagtt aagtcttgcc 180 aaatttgatg cccctccgga agctgttgca gccaagttag gagtgaagag atgcacggat 240 cagatgtccc ttcagaaacg aagcctcatt gcggaagtcc tggtgaaaat attgaagaaa 300 tgtagtgtgt gacatgtaaa aactttcatc ctggtttcca ctgtctttca atgacaccct 360 gatcttcact gcagaatgta aaggtttcaa cgtcttgctt taataaatca cttgctctcc 420 aaaaaaaaaa aaaaaa 436 <210> 2 <211> 90 <212> PRT
<213> Homo sapiens <400> 2 Met Lys Leu Ser Val Cys Leu Leu Leu Val Thr Leu Ala Leu Cys Cys Tyr Gln Ala Asn Ala Glu Phe Cys Pro Ala Leu Val Ser Glu Leu Leu Asp Phe Phe Phe Ile Ser Glu Pro Leu Phe Lys Leu Ser Leu Ala Lys Phe Asp Ala Pro Pro Glu Ala Val Ala Ala Lys Leu Gly Val Lys Arg Cys Thr Asp Gln Met Ser Leu Gln Lys Arg Ser Leu Ile Ala Glu Val Leu Val Lys Ile Leu Lys Lys Cys Ser Val
In all of these cancers, chances of survival are much better if the cancer is diagnosed at an early stage. Further, treatment decisions for the individual are linked to the stage of the cancer present in that individual. However, current cancer staging methods are limited and some such cancers initially staged as not metastatic are actually metastatic.
For example, as many as 500 of the cases of prostate cancer initially staged as A2, B, or C are actually stage D, metastatic. Discovery of metastasis is significant because patients with metastatic cancers have a poorer prognosis and require significantly different therapy than those with localized cancers.
Accordingly, there is a great need for sensitive and accurate methods for early detection and staging of gynecologic cancers such as endometrial, breast, uterine and ovarian cancer and prostate cancer in humans.
Steroid binding proteins, including uteroglobin and CC10, are a class of proteins which bind steroids along with methylsulfonyl metabolites of polychlorinated biphenyls. The exact function of members of this class of protein is uncertain. However, uteroglobin has been shown to inhibit PLA2 mediated responses.
Gene and gene products homologous to uteroglobin are described in WO 97/34997 entitled Human Endometrial Specific Steroid Binding Factors I, II and III. The genes and their encoded products are referred to as Human Endometrial Specific Steroid-Binding Factors I, II and III (hESF I, II, and III).
Methods for utilizing these genes and gene products in research and diagnostic and clinical arts are disclosed.
In particular, methods for detecting mutations in the hESFI, II or III gene or altered protein expression resulting from a mutant gene are indicated to be useful in diagnosing, susceptibility to asthma and endometrial cancer.
A novel member of the uteroglobin family which is very similar to hESF II, referred to as BU101, is also described in WO 98/07857. BU101 is disclosed to be over-expressed in a percentage of breast tumors. Therefore, BU101 is suggested to be useful for the detecting, diagnosing staging, monitoring, prognosticating, preventing, treating and determining the predisposition of an individual to diseases and conditions of the breast such as breast cancer.
In WO 98/56248 methods for diagnosing breast cancer, endometrial cancer, endometriosis and endometrial fibroids via detection of a gene or gene product referred to therein as ESBPII and identical to BU101 are disclosed.
It has now been found that detection of ESBPII is also useful in diagnosing, monitoring, staging, prognosticating, imaging and treating uterine, ovarian and prostate cancer.
Accordingly, in the present invention, methods are provided for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating prostate cancer and gynecologic cancers including not only breast and endometrial cancer, but also uterine and ovarian cancer via ESBPII.
ESBPII refers, among other things, to native protein expressed by the gene comprising the polynucleotide sequence of SEQ ID
NO:1. The amino acid sequence of a polypeptide encoded by SEQ
ID N0:1 is depicted herein as SEQ ID N0:2. In the alternative, what is meant by the ESBPII as used herein, means the native mRNA encoded by the gene comprising the polynucleotide sequence of SEQ ID N0:1 or levels of the gene comprising the polynucleotide sequence of SEQ ID NO:1.
Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.
SUN~1ARY OF THE INVENTION
Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of prostate cancer or gynecologic cancers by analyzing for changes in levels of ESBPII in cells, tissues or bodily fluids compared with levels of ESBPII in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein a change in levels of ESBPII in the patient versus the normal human control is associated with prostate cancer or a gynecologic cancer.
Further provided is a method of diagnosing metastatic prostate cancer or a metastatic gynecologic cancer in a patient which is not known to have metastasized by identifying a human patient suspected of having prostate cancer or a gynecologic cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for ESBPII; and comparing the ESBPII levels in such cells, tissues, or bodily fluid with levels of ESBPII in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in ESBPII levels in the patient versus the normal human control is associated with prostate cancer or a gynecologic cancer which has metastasized.
Also provided by the invention is a method of staging prostate cancer or a gynecologic cancer in a human by identifying a human patient having prostate cancer or a gynecologic cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for ESBPII; comparing ESBPII
levels in such cells, tissues, or bodily fluid with levels of ESBPII in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in ESBPII
levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of ESBPII is associated with a cancer which is regressing or in remission.
Further provided is a method of monitoring prostate cancer or a gynecologic cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for ESBPII;
comparing the ESBPII levels in such cells, tissue, or bodily fluid with levels of ESBPII in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in ESBPII levels in the patient versus the normal human control is associated with a cancer which has metastasized.
Further provided is a method of monitoring the change in stage of prostate cancer or a gynecologic cancer in a human patient by monitoring levels of ESBPII in the patient. The method comprises identifying a human patient having prostate cancer or a gynecologic cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for ESBPII; comparing the ESBPII levels in such cells, tissue, or bodily fluid with levels of ESBPII in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in ESBPII levels in the patient versus the normal human control is associated with a cancer _ g _ which is progressing and a decrease in the levels of ESBPII
is associated with a cancer which is regressing or in remission.
Further provided are antibodies which specifically bind ESBPII or fragments of such antibodies which can be used to detect or image localization of ESBPII in a patient for the purpose of detecting or diagnosing prostate cancer or a gynecologic cancer. Such antibodies can be polyclonal, monoclonal, or omniclonal or prepared by molecular biology techniques. The term "antibody", as used herein and throughout the instant specification is also meant to include aptamers and single-stranded oligonucleotides such as those derived from an in vitro evolution protocol referred to as SELEX and well known to those skilled in the art. Antibodies can be labeled with a variety of detectable labels including, but not limited to, radioisotopes and paramagnetic metals.
These antibodies or fragments thereof can also be used as therapeutic agents in the treatment of diseases characterized by expression of a ESBPII. In therapeutic applications, the antibody can be used without or with derivatization to a cytotoxic agent such as a radioisotope, enzyme, toxin, drug or a prodrug.
Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.
_ g _ DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging and prognosticating cancers by comparing levels of ESBPII with those of ESBPII in a normal human control. What is meant by levels of ESBPII as used herein, means levels of the native protein expressed by the gene comprising the polynucleotide sequence of SEQ ID NO:1.
The polypeptide encoded by this polynucleotide sequence is depicted in SEQ ID N0:2. In the alternative, what is meant by levels of ESBPII as used herein, mean levels of the native mRNA encoded by the gene comprising the polynucleotide sequence of SEQ ID NO:l or levels of the gene comprising the polynucleotide sequence of SEQ ID NO:1. Such levels are I5 preferably measured in at least one of cells, tissues and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing overexpression of ESBPII
protein compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of cancers, including prostate cancer and gynecologic cancers such as uterine, endometrial, breast and ovarian cancer.
All the methods of the present invention may optionally include measuring levels of other cancer markers as well as ESBPII. Other cancer markers, in addition to ESBPII, useful in the present invention will depend on the cancer being tested and are known to those of skill in the art.
Diagnostic Assays The present invention provides methods for diagnosing the presence of prostate cancer or gynecologic cancers including breast, uterine, ovarian and endometrial cancer by analyzing for changes in levels of ESBPII in cells, tissues or bodily fluids of a human patient compared with levels of ESBPII in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein an increase in levels of ESBPII in the patient versus the normal human control is associated with the presence of prostate cancer or a gynecologic cancer.
Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues or bodily fluid levels of the cancer marker, such as ESBPII, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control.
The present invention also provides a method of diagnosing the onset of metastasis in human patients with a gynecologic cancer or prostate cancer. In this method, a human cancer patient suspected of having a gynecologic cancer or prostate cancer which may have metastasized (but which was not previously known to have metastasized) is identified.
This is accomplished by a variety of means known to those of skill in the art.
In the present invention, determining the presence of ESBPII levels in cells, tissues or bodily fluid, is particularly useful for discriminating between prostate cancer or a gynecologic cancer which has not metastasized and prostate cancer or a gynecologic cancer which has metastasized. Existing techniques have difficulty discriminating between prostate cancer or gynecologic cancers which have metastasized and prostate cancer or gynecologic cancers which have not metastasized. However, proper treatment selection is often dependent upon such knowledge.
In the present invention, the cancer marker level measured in such cells, tissues or bodily fluid is ESBPII.
Measured ESBPII levels in a human patient are compared with levels of ESBPII in preferably the same cells, tissue or bodily fluid type of a normal human control. That is, if the cancer marker being observed is ESBPII in serum, this level is preferably compared with the level of ESBPII in serum of a normal human control. An increase in the ESBPII in the patient versus the normal human control is associated with prostate cancer or a gynecologic cancer which has metastasized.
Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues or bodily fluid levels of a cancer marker, such as ESBPII, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily fluid of a normal patient.
Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing or monitoring for metastasis, normal human control may preferably include samples from a human patient that is determined by reliable methods to have prostate cancer or a gynecologic cancer which has not metastasized.
Staging The invention also provides a method of staging prostate cancer or gynecologic cancers in a human patient. The method comprises identifying a human patient having prostate cancer or a gynecologic cancer and analyzing cells, tissues or bodily fluid from such human patient for levels of ESBPII.
The levels of ESBPII in the patient are then compared to levels of ESBPII in preferably the same cells, tissues or bodily fluid type of a normal human control, wherein an increase in ESBPII levels in the human patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of ESBPII is associated with a cancer which is regressing or in remission.
Monitoring Further provided is a method of monitoring prostate cancer or gynecologic cancers in a human patient having such cancer for the onset of metastasis. The method comprises identifying a human patient having prostate cancer or a gynecologic cancer that is not known to have metastasized;
periodically analyzing cells, tissues or bodily fluid from such human patient for ESBPII; comparing the ESBPII levels in such cells, tissues or bodily fluid with levels of ESBPII in preferably the same cells, tissues or bodily fluid type of a normal human control, wherein an increase in ESBPII levels in the human patient versus the normal human control is associated with a cancer which has metastasized.
Further provided by this invention is a method of monitoring the change in stage of prostate cancer or a gynecologic cancer in a human having such cancer. The method comprises identifying a human patient having prostate cancer or a gynecologic cancer; periodically analyzing cells, tissues or bodily fluid from such human patient for ESBPII; and comparing the ESBPII levels in such cells, tissues or bodily fluid with levels of ESBPII in preferably the same cells, tissues or bodily fluid type of a normal human control sample, wherein an increase in ESBPII levels in the human patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of ESBPII is associated with a cancer which is regressing in stage or in remission.
Monitoring such patient for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.
Assay Techniques Assay techniques that can be used to determine levels of gene expression (including protein levels), such as ESBPII
of the present invention, in a sample derived from a patient are well known to those of skill in the art. Such assay methods include, without limitation, radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, in situ hybridization assays, competitive-binding assays, Western Blot analyses, ELISA
assays and proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel based approaches such as mass spectrometry or protein interaction profiling. Among these, ELISAs are frequently preferred to diagnose a gene's expressed protein in biological fluids.
An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to ESBPII, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds specifically to ESBPII. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent. Examples include, but are not limited to, horseradish peroxidase enzyme and alkaline phosphatase.
To carry out the ELISA, antibody specific to ESBPII is incubated on a solid support, e.g. a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time ESBPII
binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to ESBPII and linked to a detectable reagent such as horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to ESBPII. Unattached reporter antibody is then washed out. Reagents for peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to ESBPII
antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of ESBPII protein present in the sample.
Quantitative results typically are obtained by reference to a standard curve.
A competition assay can also be employed wherein antibodies specific to ESBPII are attached to a solid support and labeled ESBPII and a sample derived from the host are passed over the solid support. The amount of label detected which is attached to the solid support can be correlated to a quantity of ESBPII in the sample.
Nucleic acid methods can also be used to detect ESBPII
mRNA as a marker for prostate cancer and gynecologic cancers.
Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA
species is first reverse transcribed to complementary DNA
(cDNA) with use of the enzyme reverse transcriptase; the cDNA
is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.
Hybridization to clones or oligonucleotides arrayed on a solid support (i.e. gridding) can be used to both detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the ESBPII gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or plastic. At least a portion of the DNA encoding the ESBPII
gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest.
Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be done by comparison of the intensity of the signal from the analyte compared with that determined from known standards.
The standards can be obtained by in vitro transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.
Of the proteomic approaches, 2D electrophoresis is a technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels.
First, proteins are separated by size using an electric current. The current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins.
The second dimension applies a current perpendicular to the first and separates proteins not on the basis of size but on the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot.
Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.
The above tests can be carried out on samples derived from a variety of cells, bodily fluids and/or tissue extracts (homogenates or solubilized tissue) obtained from the patient including tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof. Blood can include whole blood, plasma, serum or any derivative of blood.
In Vivo Antibody Use Antibodies against ESBPII can also be used in vivo in patients suspected of suffering from prostate cancer or gynecologic cancers such as ovarian, breast, endometrial and uterine cancer. Specifically, antibodies against a ESBPII can be injected into a patient suspected of having prostate cancer or a gynecologic cancer for diagnostic and/or therapeutic, purposes. The use of antibodies for in vivo diagnosis is well known in the art. For example, antibody-chelators labeled with Indium-111 have been described for use in the radioimmunoscintographic imaging of carcinoembryonic antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990 17:247-259). In particular, these antibody-chelators have been used in detecting tumors in patients suspected of having recurrent colorectal cancer (Griffin et al. J. Clin. Onc. 1991 9:631-640). Antibodies with paramagnetic ions as labels for use in magnetic resonance imaging have also been described (Lauffer, R.B. Magnetic Resonance in Medicine 1991 22:339-342). Antibodies directed against ESBPII can be used in a similar manner. Labeled antibodies against ESBPII can be injected into patients suspected of having a gynecologic cancer or prostate cancer for the purpose of diagnosing or staging of the disease status of the patient. The label used will be selected in accordance with the imaging modality to be used. For example, radioactive labels such as Indium-111, Technetium-99m or Iodine-131 can be used for planar scans or single photon emission computed tomography (SPELT). Positron emitting labels such as Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadlinium (III) or Manganese (II) can be used in magnetic resonance imaging (MRI). Localization of the label permits determination of the spread of the cancer. The amount of label within an organ or tissue also allows determination of the presence or absence of cancer in that organ or tissue.
For patients diagnosed with prostate cancer or a gynecologic cancer, injection of an antibody against ESBPII
can also have a therapeutic benefit. The antibody may exert its therapeutic effect alone. Alternatively, the antibody is conjugated to a cytotoxic agent such as a drug, toxin or radionuclide to enhance its therapeutic effect. Drug monoclonal antibodies have been described in the art for example by Garnett and Baldwin, Cancer Research 1986 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various cancers has also been described by Pastan et al. Cell 1986 97:641-648. Yttrium-90 labeled monoclonal antibodies have been described for maximization of dose delivered to the tumor while limiting toxicity to normal tissues (Goodwin and Meares Cancer Supplement 1997 80:2675-2680). Other cytotoxic radionuclides including, but not limited to Copper-67, Iodine-131 and Rhenium-186 can also be used for labeling of antibodies against ESBPII.
Antibodies which can be used in these in vivo methods include both polyclonal, monoclonal or omniclonal antibodies and antibodies prepared via molecular biology techniques.
Antibody fragments and aptamers and single-stranded oligonucleotides such as those derived from an in vitro evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.
The present invention is further described by the following examples. These examples are provided solely to illustrate the invention by reference to specific embodiments.
These exemplifications, while illustrating certain aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.
EXAMPLES
The examples are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. Routine molecular biology techniques of the following example can be carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
(1989) .
Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye.
During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).
Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ATP synthase 6 (ATPsy6), or 18S ribosomal RNA (rRNA} is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA
levels for one sample are used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).
The tissue distribution and the level of the target gene for every example was evaluated in normal and cancer tissue.
Total RNA was extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was done using primers and Taqman probe specific to the target gene. The results were analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.
The absolute numbers depicted in Table 1 are relative levels of expression of ESBPII in 12 normal different tissues.
All the values are compared to normal lung (calibrator).
These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.
Table 1: Relative Levels of ESBPII Expression in Pooled Samples TISSUE NORMAL
Brain 28 Heart 50 Kidney 374 Liver 3 Lung 1 Breast 10885 Prostate 590 Small Intestine 60 Spleen 1 Testis 308 Thymus 8 Uterus 16047 The relative levels of expression in Table 1 show that the highest level of expression of ESBPII mRNA is in uterus (16047) and the second highest levels of expression is in mammary gland (10885). Prostate (590), kidney (374), and testis (308) also express mRNA for ESBPII. These results established that ESBPII mRNA expression is highly specific for uterus and breast in female tissues, and prostate for male tissues.
The absolute numbers in Table 1 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 2.
The absolute numbers depicted in Table 2 are relative levels of expression of ESBPII in 76 pairs of matching samples, ovarian cancer samples from 15 different individuals, and normal ovarian samples from 15 different individual s. All the values are compared to normal lung (calibrator). A
matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.
Table 2: Relative Levels of ESBPII Expression in Pooled Samples Sample ID Tissue Cancer Normal Normal Adjacent Tissue End10479 Endometrium 1 1189 143 End8911 Endometrium 2 989 15772 END012XA Endometrium 3 2226 6724 END028XA Endometrium 9 14767 6701 END03AX Endometrium 5 1284 2864 END05XA Endometrium 6 20857 38388 END065RA Endometrium 7 151825 1515 END08XA Endometrium 8 115 4097 End8963 Endometrium 9 149010 13308 End4XA Endometrium 10 274 12945 End68X Endometrium 11 751834 759691 BLD32XK Bladder 1 1 0 BLD46XK Bladder 2 26 21 CLNAS45 Colon 1 1 1 CLNRCO1 Colon 2 0 2 C1nB34 Colon 3 0 3 CvxKS52 Cervix 1 0 17 CvxNKSl8 Cervix 2 0 20 CvxNKs80 Cervix 3 0 778347 Kid107XD Kidney 1 1734 1239 Kid106XD Kidney 2 125 699 Kid109XD Kidney 3 274 637 KidlOXD Kidney 4 5814 1892 KidllXD Kidney 5 423 537 Kid124D Kidney 6 100 332 Kidl2XD Kidney 7 467 287 Kid150D Kidney 8 1862 134 Kid373K Kidney 9 388 330 KidSXD Kidney 10 1239 1061 Kid98XD Kidney 11 100 391 LIV15XA Liver 1 3 2 Liv94XA Liver 2 39 0 Lng60XL Lung 1 0 2 LngSQ81 Lung 2 0 12 LNGC20X Lung 3 5 26 Mam47XP Breast 1 1448 177 Mam82XI Breast 2 24 246 MamA06X Breast 3 10865 6047 MamBOIIX Breast 4 12915 1194 Mam59X Breast 5 648 119 MamS079 Breast 6 24 33 MamS123 Breast 7 81282 1598 MamS516 Breast 8 5827 987 MamS570 Breast 9 6125 15555 PAN71XL Pancreas 1 12 18 Pan82XP Pancreas 2 56 383 Pan77X Pancreas 3 0 0 Prol8XB Prostate 1 959 2798 Pro20XB Prostate 2 9642 2084 Pro69XB Prostate 3 2041 171 Pro90XB Prostate 4 251 3916 Pro65XB Prostate 5 1296 832 Pro101XB Prostate 6 2896 5753 Prol2B Prostate 7 2750 111 Prol3XB Prostate 8 33 551 Pro23B Prostate 9 310 309 Pro34B Prostate 10 1261 1180 Pro78XB Prostate 11 666 697 Pro84XB Prostate 12 3214 972 Pro9lX Prostate 13 3835 989 ProC215 Prostate 19 5312 nd ProC234 Prostate 15 549 nd ProC280 Prostate 16 873 nd SmInt2lXA Small Intestine 9 12 SmInH89 Small Intestine 2 25 StoAC44 Stomach 1 4 4 StoAC99 Stomach 2 3 2 Tst39X Testis 1 29 146 UTR135X0 Uterus 1 2055 3616 UTR141X0 Uterus 2 69516 8024 UTR85XU Uterus 3 2947 7083 UTR23XU Uterus 4 52501 6361 Ovr103X Ovary 1 760 4 Ovr130X Ovary 2 1 77 OvrG010 Ovary 3 1670 108 OvrG021 Ovary 4 6 21 Ovr1005 Ovary Cancer 1 4716 Ovr1040 Ovary Cancer 2 2235 Ovr638A Ovary Cancer 3 6 Ovr63A Ovary Cancer 4 9 Ovr1028 Ovary Cancer 5 8 Ovr1050 Ovary Cancer 6 629 Ovr1118 Ovary Cancer 7 2 Ovr1157 Ovary Cancer 8 2694 Ovr130X Ovary Cancer 9 1587 Ovr1461 Ovary Cancer 10 0 Ovr180B Ovary Cancer 11 3104 Ovr3710 Ovary Cancer 12 803 Ovr63A Ovary Cancer 13 7 OvrAlC Ovary Cancer 14 4251 OvrC360 Ovary Cancer 15 3 OvrlBGA Ovary Normal 1 4 Ovr2061 Ovary Normal 2 28 Ovr20GA Ovary Normal 3 Ovr230A Ovary Normal 4 28 Ovr233A Ovary Normal 5 0 Ovr247A Ovary Normal 6 113 Ovr25GA Ovary Normal 7 88 Ovr32RA Ovary Normal 8 47 Ovr6380 Ovary Normal 9 23 OvrC0009 Ovary Normal 10 16 OvrC179 Ovary Normal 11 8 Ovr35GA Ovary Normal 12 18 Ovr40G Ovary Normal 13 1 Ovr50GB Ovary Normal 14 2 Ovr9RA Ovary Normal 15 2 0= Negative nd=Not Determined In the analysis of matching samples, the higher levels of expression were in uterus, endometrium, breast, ovary, and prostate. There is also a lower expression of ESBPII in the kidney matching samples analyzed. The median expression in the kidney cancer samples (423), is one third the median expression in the prostate cancer samples (1279). This pattern shows a high degree of specificity for female gynecologic tissues and prostate tissue. These results confirmed the tissue specificity results obtained with the panel of normal pooled samples (Table 1) for uterus, breast and prostate.
Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e. g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 2 shows overexpression of ESBPII in 4 primary endometrial cancer tissues compared with their respective normal adjacent (endometrium samples #l, 4, 7, and 9). There was overexpression in the cancer tissue for 36.36 of the endometrial matching samples tested (total of 11 endometrium matching samples).
ESBPII is differentially expressed in the four matching samples for uterine cancer. Samples #1 and 3 show downregulation for the mRNA of ESBPII in cancer, whereas samples #2 and #4 show overexpression in the cancer samples.
Of nine breast cancer matching samples analyzed, three showed underexpression of ESBPII (#2, 6, and 9) in cancer, whereas six had higher levels of ESBPII in cancer compared to the normal adjacent tissue (#1, 3, 4, 5, 7, and 8).
ESBPII is differentially expressed in the four matching samples for ovarian cancer. Samples #1 and 3 showed upregulation for the mRNA of ESBPII in cancer, whereas samples #2 and #4 showed overexpression in the normal adjacent tissue.
Beside the four matching samples, thirty additional ovarian samples were analyzed. Fifteen cancer samples and 15 normal ovary tissue samples from different individuals. The median expression in the ovary cancer samples (629) is four times higher than the median expression in the normal ovary samples (16) .
Altogether, the high level of tissue specificity for gynecological tissues, plus the mRNA differential expression in several of the primary uterus, endometrial, breast, and ovarian matching samples tested are indicative of ESBPII being a diagnostic marker for gynecologic cancers including uterine, endometrial, breast, and ovarian cancer. ESBPIT is also differentially expressed in the 13 matching samples for prostate cancer. Samples #l, 4, 6, 8, and 11 showed downregulation of the mRNA of ESBPII in cancer, whereas samples #2, 3, 5, 7, 9, 10, 12, and 13 showed overexpression in the cancer tissue. The median expression in the prostate cancer samples (1279) is higher than the median expression in the normal prostate samples (972).
Altogether, the high level of tissue specificity for prostate tissue, plus the mRNA differential expression in several of the primary prostate matching samples tested are indicative of ESBPII being a diagnostic marker for prostate cancer.
SEQUENCE LISTING
<110> Macina, Roberto A.
DIADEXUS LLC
<120> A Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Gynecologic Cancers and Prostate Cancer <130> DEX-0046 <140>
<141>
<150> 60/103,093 <151> 1998-10-05 <160> 2 <170> PatentIn Ver. 2.0 <210> 1 <211> 436 <212> DNA
<213> Homo Sapiens <400> 1 ttgtttgtga aagctgagct cacagcaaaa caagccacca tgaagctgtc ggtgtgtctc 60 ctgctggtca cgctggccct ctgctgctac caggccaatg ccgagttctg cccagctctt 120 gtttctgagc tgttagactt cttcttcatt agtgaacctc tgttcaagtt aagtcttgcc 180 aaatttgatg cccctccgga agctgttgca gccaagttag gagtgaagag atgcacggat 240 cagatgtccc ttcagaaacg aagcctcatt gcggaagtcc tggtgaaaat attgaagaaa 300 tgtagtgtgt gacatgtaaa aactttcatc ctggtttcca ctgtctttca atgacaccct 360 gatcttcact gcagaatgta aaggtttcaa cgtcttgctt taataaatca cttgctctcc 420 aaaaaaaaaa aaaaaa 436 <210> 2 <211> 90 <212> PRT
<213> Homo sapiens <400> 2 Met Lys Leu Ser Val Cys Leu Leu Leu Val Thr Leu Ala Leu Cys Cys Tyr Gln Ala Asn Ala Glu Phe Cys Pro Ala Leu Val Ser Glu Leu Leu Asp Phe Phe Phe Ile Ser Glu Pro Leu Phe Lys Leu Ser Leu Ala Lys Phe Asp Ala Pro Pro Glu Ala Val Ala Ala Lys Leu Gly Val Lys Arg Cys Thr Asp Gln Met Ser Leu Gln Lys Arg Ser Leu Ile Ala Glu Val Leu Val Lys Ile Leu Lys Lys Cys Ser Val
Claims (10)
1. A method for diagnosing the presence of prostate cancer or a gynecologic cancer in a patient comprising:
(a) measuring levels of ESBPII in cells, tissues or bodily fluids in a patient; and (b) comparing the measured levels of ESBPII with levels of ESBPII in cells, tissues or bodily fluids from a normal human control, wherein a change in measured levels of ESBPII
in said patient versus normal human control is associated with the presence of prostate cancer or a gynecologic cancer.
(a) measuring levels of ESBPII in cells, tissues or bodily fluids in a patient; and (b) comparing the measured levels of ESBPII with levels of ESBPII in cells, tissues or bodily fluids from a normal human control, wherein a change in measured levels of ESBPII
in said patient versus normal human control is associated with the presence of prostate cancer or a gynecologic cancer.
2. A method of diagnosing metastases of prostate cancer or a gynecologic cancer in a patient comprising:
(a) identifying a patient having a prostate cancer or a gynecologic cancer that is not known to have metastasized;
(b) measuring ESBPII levels in cells, tissues, or bodily fluid from said patient; and (c) comparing the measured ESBPII levels with levels of ESBPII in cells, tissue, or bodily fluid of a normal human control, wherein an increase in measured ESBPII levels in the patient versus the normal human control is associated with a cancer which has metastasized.
(a) identifying a patient having a prostate cancer or a gynecologic cancer that is not known to have metastasized;
(b) measuring ESBPII levels in cells, tissues, or bodily fluid from said patient; and (c) comparing the measured ESBPII levels with levels of ESBPII in cells, tissue, or bodily fluid of a normal human control, wherein an increase in measured ESBPII levels in the patient versus the normal human control is associated with a cancer which has metastasized.
3. A method of staging prostate cancer or a gynecologic cancer in a patient having prostate cancer or a gynecologic cancer comprising:
(a) identifying a patient having prostate cancer or a gynecologic cancer;
(b) measuring ESBPII levels in cells, tissue, or bodily fluid from said patient; and (c) comparing measured ESBPII levels with levels of ESBPII in cells, tissues, or bodily fluid of a normal human control, wherein an increase in measured ESBPII levels in said patient versus the normal human control is associated with a cancer which is progressing and a decrease in the measured ESBPII levels is associated with a cancer which is regressing or in remission.
(a) identifying a patient having prostate cancer or a gynecologic cancer;
(b) measuring ESBPII levels in cells, tissue, or bodily fluid from said patient; and (c) comparing measured ESBPII levels with levels of ESBPII in cells, tissues, or bodily fluid of a normal human control, wherein an increase in measured ESBPII levels in said patient versus the normal human control is associated with a cancer which is progressing and a decrease in the measured ESBPII levels is associated with a cancer which is regressing or in remission.
4. A method of monitoring prostate cancer or a gynecologic cancer in a patient for the onset of metastasis comprising:
(a) identifying a patient having prostate cancer or a gynecologic cancer that is not known to have metastasized;
(b) periodically measuring levels of ESBPII cells, tissues, or bodily fluid from said patient; and (c) comparing the periodically measured ESBPII levels with levels of ESBPII in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured ESBPII levels in the patient versus the normal human control is associated with a cancer which has metastasized.
(a) identifying a patient having prostate cancer or a gynecologic cancer that is not known to have metastasized;
(b) periodically measuring levels of ESBPII cells, tissues, or bodily fluid from said patient; and (c) comparing the periodically measured ESBPII levels with levels of ESBPII in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured ESBPII levels in the patient versus the normal human control is associated with a cancer which has metastasized.
5. A method of monitoring the change in stage of prostate cancer or a gynecologic cancer in a patient comprising:
(a) identifying a patient having prostate cancer or a gynecologic cancer;
(b) periodically measuring levels of ESBPII in cells, tissues, or bodily fluid from said patient; and (c) comparing the periodically measured ESBPII levels with levels of ESBPII in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured ESBPII levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.
(a) identifying a patient having prostate cancer or a gynecologic cancer;
(b) periodically measuring levels of ESBPII in cells, tissues, or bodily fluid from said patient; and (c) comparing the periodically measured ESBPII levels with levels of ESBPII in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured ESBPII levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.
6. The method of claim 1, 2, 3, 4 or 5 wherein the ESBPII comprises SEQ ID NO:1 or SEQ ID NO:2.
7. A method of imaging prostate cancer or a gynecologic cancer in a patient comprising administering to the patient an antibody which specifically binds to ESBPII.
8. The method of claim 7 wherein said antibody is labeled with paramagnetic ions or a radioisotope.
9. A method of treating prostate cancer or a gynecologic cancer in a patient comprising administering to the patient an antibody which specifically binds to ESBPII.
10. The method of claim 9 wherein the antibody is conjugated to a cytotoxic agent.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10309398P | 1998-10-05 | 1998-10-05 | |
| US60/103,093 | 1998-10-05 | ||
| PCT/US1999/023252 WO2000020043A1 (en) | 1998-10-05 | 1999-10-05 | A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2346326A1 true CA2346326A1 (en) | 2000-04-13 |
Family
ID=22293359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002346326A Abandoned CA2346326A1 (en) | 1998-10-05 | 1999-10-05 | A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1128848A4 (en) |
| JP (1) | JP2002526752A (en) |
| CA (1) | CA2346326A1 (en) |
| WO (1) | WO2000020043A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7014996B1 (en) | 1998-10-02 | 2006-03-21 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers |
| GB0102562D0 (en) | 2001-02-01 | 2001-03-21 | Unilever Plc | Cosmetic products for the reduction of sweat acidity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998007857A1 (en) * | 1996-08-19 | 1998-02-26 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| CA2270156A1 (en) * | 1996-11-12 | 1998-05-22 | Incyte Pharmaceuticals, Inc. | Human breast tumor-specific proteins |
| DE69830169T2 (en) * | 1997-06-09 | 2006-02-16 | Smithkline Beecham Corp. | PROOF AND TREATMENT OF CANCER |
| WO1999045147A1 (en) * | 1998-03-05 | 1999-09-10 | Diadexus Llc | A novel method of detecting and monitoring endometrial and uterine cancers |
-
1999
- 1999-10-05 WO PCT/US1999/023252 patent/WO2000020043A1/en not_active Application Discontinuation
- 1999-10-05 CA CA002346326A patent/CA2346326A1/en not_active Abandoned
- 1999-10-05 EP EP99954757A patent/EP1128848A4/en not_active Withdrawn
- 1999-10-05 JP JP2000573401A patent/JP2002526752A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000020043A1 (en) | 2000-04-13 |
| EP1128848A1 (en) | 2001-09-05 |
| EP1128848A4 (en) | 2002-08-28 |
| JP2002526752A (en) | 2002-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1109937B1 (en) | METHOD OF DIAGNOSING, MONITORING, STAGING, and IMAGING VARIOUS CANCERS | |
| US7858325B2 (en) | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer | |
| US7326529B2 (en) | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer | |
| US7432064B2 (en) | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer | |
| EP1105528A1 (en) | A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer | |
| EP1131095A1 (en) | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer | |
| CA2347656A1 (en) | A novel method of diagnosing, monitoring, staging, imaging and treating lung cancer | |
| WO2000007632A1 (en) | A novel method of diagnosing, monitoring, staging, imaging and treating colon cancer | |
| WO2000020640A1 (en) | A novel method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancers | |
| WO2000023108A1 (en) | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer | |
| US7014996B1 (en) | Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers | |
| US6962779B1 (en) | Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancers | |
| CA2345285A1 (en) | A novel method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers | |
| CA2346326A1 (en) | A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers | |
| EP1115426A1 (en) | Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers and testicular cancer | |
| US7326402B2 (en) | Method of diagnosing, monitoring, staging, imaging and treating cancer | |
| US20050106620A1 (en) | Novel method of diagnosing, monitoring, staging, imaging and treating cancer | |
| WO2000012761A1 (en) | A novel antibody for the diagnosis of bladder cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |